Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, reported first quarter 2026 results highlighted by a 196% year-over-year increase in Nociscan scan volumes, reflecting accelerating clinical adoption and integration into clinical workflows. The company also achieved 64% sequential scan volume growth compared to Q4 2025, driven by new account activation and deeper utilization within existing sites.
The strong performance underscores the growing value proposition of Nociscan, a SaaS platform that uses biomarkers and augmented intelligence to help physicians identify the location of chronic low back pain. With approximately 5.8 million lumbar MRIs performed annually in the U.S. for low back pain, Aclarion sees a potential $2 billion market opportunity for technologies like Nociscan that provide objective, data-driven evaluation of discogenic pain.
Key catalysts driving growth include reimbursement from three of the four largest private insurers in the U.K.—Vitality, AXA, and Aviva—providing a pathway for broader coverage expansion. The company also launched a targeted direct-to-patient campaign in the U.K., featuring a video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. In the U.S., Aclarion continues to engage payers through its Nociscan Reimbursement Program to establish coverage pathways.
On the clinical front, Aclarion is advancing the CLARITY randomized trial designed to validate Nociscan's clinical utility in guiding treatment decisions. A preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. The company also has seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials to support reimbursement discussions and potential local coverage decisions by commercial insurers.
Aclarion strengthened its intellectual property portfolio with a newly issued patent covering the use of AI in workflows of future products, bringing its total to 64 issued and pending patents worldwide. This enhances the company's competitive moat and ability to scale while maintaining strong gross margins.
Financially, Aclarion enters this growth phase with a solid foundation. As of March 31, 2026, the company had $19.0 million in cash with no debt and a clean capital structure. With 2,444,871 common shares outstanding (2,882,371 fully diluted), the company has approximately $6.60 per share in cash on a fully diluted basis. Management believes existing cash resources, combined with a $2.5 million stock buyback program announced this week, are sufficient to fund operations into the second half of 2027.
“Q1 represents a clear inflection for Aclarion,” said Brent Ness, CEO. “Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market.”
The company's latest news and updates are available in their newsroom at https://tinyurl.com/aconnewsroom. For more information on Nociscan, visit www.aclarion.com.
